MOLN MOLECULAR PARTNERS AG IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1745114 · Reporting currency CHF · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CHF | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 0 | 4.97M | 7.04M | 189.60M | 9.75M |
| R&D expense | 40.19M | 48.60M | 48.78M | 50.75M | 55.72M |
| SG&A expense | 15.24M | 17.58M | 19.36M | 22.24M | 17.45M |
| Operating income | -58.12M | -61.22M | -61.11M | 116.61M | -63.42M |
| Interest expense | 5.05M | 38,000 | 5.16M | 619,000 | 556,000 |
| Pretax income | -61.65M | -54.04M | -61.98M | 117.85M | -63.78M |
| Income tax | 2,000 | 2,000 | 0 | 0 | 2,000 |
| Net income | -61.65M | -54.04M | -61.98M | 117.85M | -63.78M |
| EBITDA | -55.98M | -58.85M | -58.69M | 119.00M | -60.85M |
| EPS (basic) | -1.65 | -1.59 | -1.89 | 3.63 | -2.06 |
| EPS (diluted) | -1.65 | -1.59 | -1.89 | 3.54 | -2.06 |
| Weighted avg. shares (diluted) | 37.27M | 34.03M | 32.77M | 33.27M | 31.01M |
| Balance sheet | |||||
| Cash & equivalents | 82.65M | 63.87M | 67.31M | 87.95M | 71.81M |
| Short-term investments | 10.40M | 85.56M | 119.58M | 161.20M | 61.00M |
| Receivables | 1.83M | 2.32M | 1.95M | 1.02M | 25.65M |
| Current assets | 96.88M | 154.28M | 192.46M | 254.75M | 164.19M |
| PP&E, netmay include right-of-use assets (IFRS) | 5.23M | 4.20M | 5.68M | 7.24M | 8.15M |
| Intangibles | 2,000 | 49,000 | 212,000 | 271,000 | 331,000 |
| Total assets | 102.11M | 158.53M | 198.35M | 262.26M | 172.67M |
| Current liabilities | 11.03M | 10.79M | 14.42M | 17.25M | 46.87M |
| Total liabilities | 21.77M | 16.89M | 21.92M | 27.09M | 65.38M |
| Shareholders' equity | 80.33M | 141.64M | 176.43M | 235.17M | 107.29M |
| Shares outstanding | 40.37M | 40.36M | 36.35M | 36.04M | 32.29M |
| Cash flow statement | |||||
| Operating cash flow | -51.26M | -59.25M | -59.01M | 118.57M | -90.95M |
| Capital expenditure | 714,000 | 705,000 | 575,000 | 1.18M | 933,000 |
| Free cash flow | -51.97M | -59.95M | -59.58M | 117.39M | -91.89M |
| Investing cash flow | 72.55M | 40.49M | 44.64M | -101.12M | -22.24M |
| Financing cash flow | -1.15M | 14.43M | -1.17M | -1.57M | 50.58M |
| Depreciation & amortization | 2.14M | 2.37M | 2.42M | 2.39M | 2.56M |
| Stock-based compensation | 4.42M | 4.11M | 5.21M | 5.09M | 4.08M |
| Share buybacks | — | 0 | 0 | 631,000 | 0 |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.